AMB-CHMINACA, alternatively known as MMB-CHMINACA or MA-CHMINACA, belongs to the family of indazole-based synthetic cannabinoids. Notably, it exhibits strong agonistic activity towards the CB1 receptor and has entered the online market as a designer drug.
|Chemical and physical data|
|Molar mass||371.481 g·mol−1|
As of May 2015, AMB-CHMINACA was added to the Fifth Schedule of the Misuse of Drugs Act (MDA) in Singapore, rendering it illegal. Additionally, on January 18, 2019, Sweden’s public health agency categorized AMB-CHMINACA as a narcotic substance.
1. What is AMB-CHMINACA?
- AMB-CHMINACA is a synthetic cannabinoid, specifically an indazole-based compound, known for its strong agonistic effects on the CB1 receptor.
2. Is AMB-CHMINACA legal in Singapore?
- No, AMB-CHMINACA has been listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) in Singapore since May 2015, making it illegal in the country.
3. How does AMB-CHMINACA affect the endocannabinoid system?
- AMB-CHMINACA exerts its effects by interacting with the CB1 receptor, a part of the endocannabinoid system in the human body. This interaction can lead to various pharmacological responses.
4. Where has AMB-CHMINACA been classified as a narcotic substance?
- Sweden’s public health agency classified AMB-CHMINACA as a narcotic substance on January 18, 2019. This classification reflects concerns about its potential risks and effects on public health.
5. What are the potential health risks associated with AMB-CHMINACA use?
- Synthetic cannabinoids like AMB-CHMINACA can have adverse effects on the endocannabinoid system and may lead to a range of health risks, including psychological and physical side effects.
6. Is AMB-CHMINACA still available as a designer drug in other countries?
- The availability of AMB-CHMINACA as a designer drug may vary from one region to another. It’s important to check local laws and regulations regarding this substance to determine its current legal status.
7. Are there ongoing studies or regulations related to AMB-CHMINACA?
- Research and regulatory efforts continue to monitor synthetic cannabinoids like AMB-CHMINACA better to understand their properties, effects, and potential risks. Staying informed about any changes in regulations or research findings is crucial.
- Akamatsu S, Yoshida M (January 2016). “Analysis of synthetic cannabinoids with isopropyl and tert-butyl groups: A study of their fragmentation using electron impact and electrospray ionization.” Journal of Mass Spectrometry. This research explores the fragmentation patterns of synthetic cannabinoids featuring isopropyl and tert-butyl groups. [doi:10.1002/jms.3722]
- “MA-CHMINACA.” Cayman Chemical. Detailed information on MA-CHMINACA, a synthetic cannabinoid. [Retrieved 21 July 2015]
- “MA-CHMINACA.” Southern Association of Forensic Scientists. Archived resource providing insights into MA-CHMINACA. [Retrieved 21 July 2015]
- Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, et al. (September 2016). “Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids.” ACS Chemical Neuroscience. This study delves into the pharmacology of various synthetic cannabinoids, including 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, and MDMB-CHMICA, and their analogues. [doi:10.1021/acschemneuro.6b00137]
- “CNB NEWS RELEASE.” Central Narcotics Bureau (CNB). Information from the Central Narcotics Bureau regarding synthetic cannabinoids. [Archived from the original on 15 July 2015]
- “Sexton nya ämnen klassas som narkotika eller hälsofarlig vara” [Sixteen new substances classified as narcotics or dangerous to health] (in Swedish). Folkhälsomyndigheten. An update from the Swedish Public Health Agency on substances classified as narcotics or posing health risks. [Archived from the original on 3 June 2021; Retrieved 11 November 2019]